10-Q: Zomedica Q2: Revenue Up, Impairment Hits Net Loss

Zomedica Corp. reported increased revenue for Q2 2025, but a significant impairment charge in Q1 led to a higher net loss for the six-month period.

Summary

• Net revenue for the three months ended June 30, 2025, increased by 14% to $6,964 thousand from $6,131 thousand in the prior year.
• Net revenue for the six months ended June 30, 2025, increased by 9% to $13,464 thousand from $12,393 thousand in the prior year.
• Gross profit margin decreased to 67% for both the three and six months ended June 30, 2025, compared to 71% and 68% respectively, in the prior year periods.
• General and administrative expenses decreased by 23% to $6,162 thousand for the three months and 25% to $12,424 thousand for the six months ended June 30, 2025.
• Research and development expenses increased by 25% to $1,886 thousand for the three months and 14% to $3,739 thousand for the six months ended June 30, 2025.
• Selling and marketing expenses increased by 19% to $4,653 thousand for the three months and 20% to $9,660 thousand for the six months ended June 30, 2025.
• A significant non-cash impairment expense of $55,833 thousand was recorded for the six months ended June 30, 2025, primarily in the first quarter, compared to $16,024 thousand in the prior year period.
• Net loss for the three months ended June 30, 2025, improved to $(7,398) thousand from $(23,931) thousand in the prior year, largely due to the absence of impairment charges in the current quarter.
• Net loss for the six months ended June 30, 2025, increased to $(71,207) thousand from $(33,091) thousand in the prior year, driven by the substantial impairment expense.
• Cash and cash equivalents increased to $8,129 thousand as of June 30, 2025, from $7,021 thousand at December 31, 2024.
• Net cash used in operating activities decreased to $(12,090) thousand for the six months ended June 30, 2025, from $(14,309) thousand in the prior year period.
• Total assets decreased to $136,472 thousand as of June 30, 2025, from $207,360 thousand at December 31, 2024, primarily due to the impairment of goodwill and intangible assets.
• Accumulated deficit increased to $(289,122) thousand as of June 30, 2025, from $(217,915) thousand at December 31, 2024.

Sentiment

Score: 4

Explanation: While revenue growth and improved operational cash flow are positive, the very large impairment charges for the six-month period, reflecting a significant write-down of asset values and the impact of NYSE American delisting, heavily weigh down the sentiment. The company continues to incur substantial net losses, indicating ongoing challenges to profitability despite operational efficiencies.

Positives

• Net revenue increased by 14% for the three months and 9% for the six months ended June 30, 2025, driven by growth in TRUFORMA products (including new assays), existing Assisi products, PulseVet consumables, and new VETIGEL sales.
• General and administrative expenses decreased significantly by 23% for the three months and 25% for the six months, primarily due to non-recurring professional fees, lower stock-based compensation, and reduced special meeting/proxy fees.
• Net cash used in operating activities decreased by 16% for the six months ended June 30, 2025, indicating improved operational cash efficiency.
• Net cash provided by investing activities increased by 39% for the six months, primarily due to decreased capital expenditures and increased securities maturities.
• Cash and cash equivalents increased by $1,108 thousand from the beginning of the year to $8,129 thousand as of June 30, 2025.
• Net loss for the three months ended June 30, 2025, significantly improved by 69% compared to the same period in 2024, largely due to the absence of impairment expense in the current quarter.

Negatives

• Gross profit margin decreased to 67% for both the three and six months ended June 30, 2025, primarily due to higher depreciation expense from capital projects and changes in product mix.
• A substantial non-cash impairment expense of $55,833 thousand was recognized for the six months ended June 30, 2025, including full impairment of goodwill in the PulseVet and Assisi reporting units ($45,555 thousand), impairment of amortizable intangible assets ($8,297 thousand), and property and equipment ($1,981 thousand).
• Net loss for the six months ended June 30, 2025, increased by 115% to $(71,207) thousand, primarily due to the significant impairment charges.
• Total assets decreased significantly by $70,888 thousand, or 34%, from December 31, 2024, to June 30, 2025, mainly due to the asset impairments.
• Accumulated deficit increased by $71,207 thousand to $(289,122) thousand as of June 30, 2025, reflecting continued losses.
• The company's common shares were delisted from NYSE American, which was a triggering event for the significant impairment charges.

Risks

• Adverse macroeconomic conditions, geopolitical tensions, and changes in government laws and policies could impact operations.
• Changes in consumer confidence and spending in response to economic volatility may affect product demand.
• Ability to develop and commercialize products successfully is crucial for future performance.
• Successful integration of acquisitions into the business is necessary to realize expected benefits.
• Supply chain disruptions could increase costs and impair manufacturing capabilities.
• Ability to attract and retain senior management and key scientific personnel is vital for innovation and operations.
• Obtaining and maintaining intellectual property protection is essential for competitive advantage.
• Accuracy of estimates regarding expenses, future revenues, and capital requirements is subject to uncertainty, and actual results may differ significantly.
• The company is exposed to a risk of loss if customers return Diagnostic instruments (TRUFORMA capital) and discontinue consumable or related service purchases, as the customer is not obligated to purchase the capital.
• Realization of anticipated revenue from Diagnostic instruments is dependent on current assumptions and forecasted models regarding placement rate and expected utilization over the instrument's ten-year life.
• Variances in the assumed return rate for therapeutic device applicators (trodes) compared to the actual rate could impact revenue estimates and customer contract liabilities.
• Future financial performance, increases in discount rates, or other market and operational factors could negatively impact the recoverability of amortizable intangible assets or property and equipment, potentially requiring additional impairment charges.
• The company expects to continue recording net losses until sufficient revenue from product sales offsets operating expenses.
• The potential impact of climate change on operations, customer needs, operating costs, and insurance availability remains uncertain and unpredictable.

Future Outlook

Management expects revenue to increase in subsequent periods as sales, marketing, and commercialization efforts intensify. Research and development expenses are anticipated to continue increasing to maintain and enhance current product lines and develop new products. Selling and marketing expenses are also expected to rise in line with product expansion and commercialization efforts. The company anticipates continuing to record net losses in future periods until sufficient revenue from product sales offsets operating expenses. Existing cash resources are believed to be sufficient to fund expected operational requirements for both the short-term (next 12 months) and long-term (beyond 12 months).

Management Comments

• "We expect revenue to increase in subsequent periods as we increase our sales, marketing, and commercialization efforts."
• "We anticipate that costs of revenue will continue to increase in subsequent periods in accordance with increased unit sales."
• "While we expect future general and administrative expense to increase, we expect it to decrease proportionally relative to sales and related product expansion."
• "We anticipate that research and development expense will continue to increase as we maintain and enhance our current product lines and develop new products."
• "We expect future selling and marketing expense to increase in line with product expansion and growth in our commercialization efforts."
• "We expect to continue to record net losses in future periods until such time as we have sufficient revenue from product sales to offset our operating expenses."
• "We believe that our existing cash is sufficient to fund our expected short-term needs (defined as the next 12 months)."
• "We believe that our existing cash resources will be sufficient to fund our expected operational requirements for the long-term period (defined as beyond the next twelve months)."

Industry Context

The company operates in the veterinary health sector, focusing on companion animals with products in diagnostics (TRUFORMA, VetGuardian, TRUVIEW) and therapeutic devices (Assisi, PulseVet, VETIGEL). The increase in R&D expenses reflects a broader industry trend of continuous innovation and development of next-generation products. The increase in selling and marketing expenses aligns with the competitive nature of the market, requiring significant commercialization efforts to drive product adoption and sales growth. The company's strategy involves leveraging acquisitions and expanding product capabilities, which is common in a consolidating and evolving industry.

Comparison to Industry Standards

• The filing does not provide specific global benchmarks or comparable company data to assess results against industry standards.
• The impairment charges, particularly the full impairment of goodwill in two reporting units, suggest a significant re-evaluation of asset values, which could indicate that prior valuations were out of step with market realities or that the company's performance in those segments fell short of expectations compared to industry peers.

Management Changes

Legal Proceedings

• Not aware of any pending or threatened material litigation claims against the company as of June 30, 2025, and continuing as of August 6, 2025.

Stakeholder Impact

• Shareholders experienced a significant decrease in total shareholders' equity due to the accumulated deficit and impairment charges, reflecting a substantial reduction in the carrying value of assets.
• Employees in the sales department have seen increased headcount, salaries, and commissions, indicating growth in commercialization efforts.
• Customers benefit from new product offerings (e.g., VETIGEL) and expanded capabilities within existing products (e.g., TRUFORMA new assays).
• Creditors may view the significant asset write-downs as a concern, though the company reports sufficient liquidity for its operational requirements.

Next Steps

• Increase sales, marketing, and commercialization efforts to drive revenue growth.
• Continue to build internal capabilities for developing, testing, and manufacturing next-generation therapeutic and diagnostic products.
• Maintain and enhance current product lines and develop new products.
• Monitor and evaluate the impact of the recently enacted 'One Big Beautiful Bill Act' tax reform legislation.

Key Dates

Recommendation

The company's financial results present a mixed picture. While revenue is growing and operational cash burn has decreased, the substantial non-cash impairment charges for goodwill and intangible assets, totaling over $55 million for the six-month period, indicate a significant re-evaluation of asset values and reflect the impact of the NYSE American delisting. This suggests that previous valuations were overly optimistic. The company continues to incur net losses, and while management projects future revenue increases, profitability remains elusive. For existing investors, holding the stock might be reasonable given the stable cash position and ongoing product development. However, the significant asset write-downs and continued unprofitability warrant caution for new investments, making a 'buy' recommendation premature until a clear path to sustained profitability is demonstrated and the impact of the asset revaluation is fully absorbed by the market.

Keywords

Veterinary health, Animal diagnostics, Animal therapeutics, TRUFORMA, PulseVet, VETIGEL, Assisi, VetGuardian, SEC filing, 10-Q, Financial results, Impairment, Revenue growth, Net loss, Cash flow, Pet care, Biotechnology